Details of the Drug

General Information of Drug (ID: DMZMSCT)

Drug Name
Cilostazol
Synonyms
cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
Indication
Disease Entry ICD 11 Status REF
Intermittent claudication BD40.00 Approved [1]
Therapeutic Class
Vasodilator Agents
Affected Organisms
Humans and other mammals
ATC Code
B01AC23: Cilostazol
B01AC: Platelet aggregation inhibitors excl. heparin
B01A: ANTITHROMBOTIC AGENTS
B01: ANTITHROMBOTIC AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 369.5
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 - 13 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.733 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.003 mg/mL [2]
Chemical Identifiers
Formula
C20H27N5O2
IUPAC Name
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
Canonical SMILES
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
InChI
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2754
ChEBI ID
CHEBI:31401
CAS Number
73963-72-1
UNII
N7Z035406B
DrugBank ID
DB01166
TTD ID
D03VPC
VARIDT ID
DR01322
INTEDE ID
DR0324
ACDINA ID
D00129
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Modulator [5]
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [7]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [9]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [10]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [11]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Protein Interaction/Cellular Processes [11]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [10]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [12]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Gene/Protein Processing [13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [12]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [14]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Intermittent claudication
ICD Disease Classification BD40.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 3A (PDE3A) DTT PDE3A 3.33E-01 1.35E-02 0.14
Organic anion transporter 3 (SLC22A8) DTP OAT3 3.89E-02 6.02E-02 4.19E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 4.64E-01 3.84E-02 2.91E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 2.66E-02 2.54E-02 2.28E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.75E-01 4.94E-02 4.06E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.38E-02 1.07E-01 8.83E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 6.62E-01 1.75E-02 1.07E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 6.76E-03 -1.19E-01 -1.54E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.50E-03 -5.35E-02 -4.77E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cilostazol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Cilostazol and Ivosidenib. Acute myeloid leukaemia [2A60] [15]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Midostaurin. Acute myeloid leukaemia [2A60] [16]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Idarubicin. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Arn-509. Acute myeloid leukaemia [2A60] [17]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Oliceridine. Acute pain [MG31] [16]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Ivabradine. Angina pectoris [BA40] [17]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Cilostazol and Bepridil. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Major Decreased metabolism of Cilostazol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Cilostazol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Posaconazole DMUL5EW Major Decreased metabolism of Cilostazol caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [17]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Levalbuterol. Asthma [CA23] [20]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Pirbuterol. Asthma [CA23] [21]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [17]
Dalfopristin DM4LTKV Major Decreased metabolism of Cilostazol caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Clarithromycin DM4M1SG Major Decreased metabolism of Cilostazol caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Cilostazol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [22]
Troleandomycin DMUZNIG Major Decreased metabolism of Cilostazol caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Eribulin. Breast cancer [2C60-2C6Y] [16]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Cilostazol caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Tucatinib DMBESUA Major Decreased metabolism of Cilostazol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [17]
Palbociclib DMD7L94 Moderate Decreased metabolism of Cilostazol caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Bosutinib. Breast cancer [2C60-2C6Y] [17]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [24]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [21]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [21]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [21]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Cilostazol and Levomilnacipran. Chronic pain [MG30] [25]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Cilostazol and Regorafenib. Colorectal cancer [2B91] [17]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Cilostazol and Intedanib. Colorectal cancer [2B91] [26]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Sevoflurane. Corneal disease [9A76-9A78] [16]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Probucol. Coronary atherosclerosis [BA80] [16]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Cilostazol and Ardeparin. Coronary thrombosis [BA43] [27]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Cilostazol and Pasireotide. Cushing syndrome [5A70] [16]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Cilostazol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [23]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Cilostazol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [28]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Cilostazol caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [23]
MK-8228 DMOB58Q Major Decreased metabolism of Cilostazol caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [17]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Cilostazol and Danaparoid. Deep vein thrombosis [BD71] [27]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Cilostazol and Rivaroxaban. Deep vein thrombosis [BD71] [29]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Cilostazol and Vilazodone. Depression [6A70-6A7Z] [25]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Cilostazol and Vortioxetine. Depression [6A70-6A7Z] [25]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Cilostazol and Milnacipran. Depression [6A70-6A7Z] [25]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Cilostazol and Desvenlafaxine. Depression [6A70-6A7Z] [25]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Cilostazol and Heme. Discovery agent [N.A.] [30]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Cilostazol and Apigenin. Discovery agent [N.A.] [31]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [16]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Deutetrabenazine. Dystonic disorder [8A02] [32]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Cilostazol and Ingrezza. Dystonic disorder [8A02] [33]
Cenobamate DM8KLU9 Moderate Decreased metabolism of Cilostazol caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Cilostazol caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Cilostazol caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Solifenacin. Functional bladder disorder [GC50] [16]
Itraconazole DMCR1MV Major Decreased metabolism of Cilostazol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [17]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [16]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Cilostazol and Avapritinib. Gastrointestinal stromal tumour [2B5B] [17]
Boceprevir DMBSHMF Major Decreased metabolism of Cilostazol caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [17]
Telaprevir DMMRV29 Major Decreased metabolism of Cilostazol caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [17]
Rifapentine DMCHV4I Moderate Increased metabolism of Cilostazol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Cilostazol caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Cobicistat DM6L4H2 Major Decreased metabolism of Cilostazol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Saquinavir DMG814N Major Decreased metabolism of Cilostazol caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [16]
Darunavir DMN3GCH Major Decreased metabolism of Cilostazol caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Cilostazol caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [36]
Levamlodipine DM92S6N Moderate Decreased metabolism of Cilostazol caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [23]
Berotralstat DMWA2DZ Major Decreased metabolism of Cilostazol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [17]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Phenolphthalein. Irritable bowel syndrome [DD91] [16]
Crizotinib DM4F29C Major Decreased metabolism of Cilostazol caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [17]
Ceritinib DMB920Z Major Decreased metabolism of Cilostazol caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [17]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cilostazol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Cilostazol and Osimertinib. Lung cancer [2C25] [38]
Selpercatinib DMZR15V Moderate Decreased metabolism of Cilostazol caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Cilostazol and Halofantrine. Malaria [1F40-1F45] [39]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Cilostazol and Hydroxychloroquine. Malaria [1F40-1F45] [40]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [17]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Cilostazol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [41]
Idelalisib DM602WT Major Decreased metabolism of Cilostazol caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [17]
IPI-145 DMWA24P Major Decreased metabolism of Cilostazol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [17]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Cilostazol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [42]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Cilostazol and Acalabrutinib. Mature B-cell lymphoma [2A85] [43]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Cilostazol and Ibrutinib. Mature B-cell lymphoma [2A85] [44]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Cilostazol and Ponatinib. Mature B-cell lymphoma [2A85] [45]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Cilostazol and Vemurafenib. Melanoma [2C30] [16]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and LGX818. Melanoma [2C30] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Cilostazol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [17]
Danazol DML8KTN Moderate Decreased metabolism of Cilostazol caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [23]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Siponimod. Multiple sclerosis [8A40] [47]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Fingolimod. Multiple sclerosis [8A40] [16]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Ozanimod. Multiple sclerosis [8A40] [48]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Romidepsin. Mycosis fungoides [2B01] [16]
Fedratinib DM4ZBK6 Major Decreased metabolism of Cilostazol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Nilotinib DM7HXWT Moderate Decreased metabolism of Cilostazol caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [23]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Cilostazol and Dasatinib. Myeloproliferative neoplasm [2A20] [49]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Cilostazol and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [50]
Netupitant DMEKAYI Major Decreased metabolism of Cilostazol caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [17]
Entrectinib DMMPTLH Moderate Decreased metabolism of Cilostazol caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [23]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Cilostazol and Dexfenfluramine. Obesity [5B80-5B81] [25]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Cilostazol and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Cilostazol and Nepafenac. Osteoarthritis [FA00-FA05] [51]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cilostazol caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [23]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Cilostazol and MK-4827. Ovarian cancer [2C73] [17]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Triclabendazole. Parasitic worm infestation [1F90] [16]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Pimavanserin. Parkinsonism [8A00] [52]
Abametapir DM2RX0I Moderate Decreased metabolism of Cilostazol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [53]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Cilostazol and Macimorelin. Pituitary gland disorder [5A60-5A61] [54]
Lefamulin DME6G97 Moderate Decreased metabolism of Cilostazol caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [55]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Cilostazol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [17]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Degarelix. Prostate cancer [2C82] [17]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Cilostazol and ABIRATERONE. Prostate cancer [2C82] [17]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Enzalutamide. Prostate cancer [2C82] [17]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Relugolix. Prostate cancer [2C82] [17]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Cilostazol and Epoprostenol. Pulmonary hypertension [BB01] [56]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Cilostazol and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [57]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Quetiapine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Aripiprazole. Schizophrenia [6A20] [47]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Cilostazol and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Paliperidone. Schizophrenia [6A20] [16]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Cilostazol and Amisulpride. Schizophrenia [6A20] [58]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Asenapine. Schizophrenia [6A20] [16]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Cilostazol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [23]
Larotrectinib DM26CQR Moderate Decreased metabolism of Cilostazol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
Armodafinil DMGB035 Moderate Decreased metabolism of Cilostazol caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [23]
LEE011 DMMX75K Major Decreased metabolism of Cilostazol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [17]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Cilostazol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [16]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Pitolisant. Somnolence [MG42] [17]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [16]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Cilostazol and Apixaban. Thrombosis [DB61-GB90] [17]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Cilostazol and Brilinta. Thrombosis [DB61-GB90] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Lenvatinib. Thyroid cancer [2D10] [16]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Cilostazol and Cabozantinib. Thyroid cancer [2D10] [59]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [60]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Cilostazol and Betrixaban. Venous thromboembolism [BD72] [61]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Propafenone. Ventricular tachyarrhythmia [BC71] [16]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Flecainide. Ventricular tachyarrhythmia [BC71] [16]
⏷ Show the Full List of 140 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cilostazol 100 mg tablet 100 mg Oral Tablet Oral
Cilostazol 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
7 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
8 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
9 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
10 Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
11 Cilostazol enhances apoptosis of synovial cells from rheumatoid arthritis patients with inhibition of cytokine formation via Nrf2-linked heme oxygenase 1 induction. Arthritis Rheum. 2010 Mar;62(3):732-41. doi: 10.1002/art.27291.
12 Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000 Jan;35(1 Pt 2):237-43. doi: 10.1161/01.hyp.35.1.237.
13 Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension. 2005 Apr;45(4):552-6. doi: 10.1161/01.HYP.0000158263.64320.eb. Epub 2005 Feb 21.
14 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
15 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
16 Canadian Pharmacists Association.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
21 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
22 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
23 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
24 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
26 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
27 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
28 Cerner Multum, Inc. "Canadian Product Information.".
29 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
30 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
31 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
32 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
33 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
34 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
36 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
37 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
40 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
41 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
42 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
43 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
44 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
45 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
46 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47 Cerner Multum, Inc. "Australian Product Information.".
48 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
49 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
50 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
51 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
52 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
53 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
55 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
56 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
57 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
58 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
59 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
60 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
61 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.